Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 8
Main Authors Amrane, Karim, Campedel, Luca, Le Meur, Coline, Abgral, Ronan, Kharroubi, Dris, Cadranel, Jacques
Format Journal Article
LanguageEnglish
Published Frontiers media 30.09.2021
Frontiers Media S.A
Subjects
ALK
Bioengineering
crizotinib
FDG-PET/CT
Life Sciences
Medicine
NSCLC
Nuclear medicine
ROS1
therapeutic assessment
Online AccessGet full text

Cover

More Information
Summary:Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[ 18 F] fluoro-D-glucose positron emission tomography-computed tomography ( 18 F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the 18 F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.
Bibliography:Edited by: Thierry MLB Vander Borght, Catholic University of Louvain, Belgium
This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine
These authors have contributed equally to this work
Reviewed by: Sebahat Ocak, CHU UCL Namur Site Godinne Namur, Belgium; Virginia Liberini, University of Turin, Italy; Angelo Castello, IRCCS Ca 'Granda Foundation Maggiore Policlinico Hospital, Italy
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2021.691253